A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A phase 3 trial of Camrelizumab, Rivoceranib in hepatocellular carcinoma, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05320692 by Jiangsu HengRui Medicine Co., Ltd., with 423 participants enrolled, started 2022-08-09 and due to reach its primary completion in 2026-07-30. Interventions recorded: TACE+Camrelizumab+Apatinib mesylate, TACE. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- TrialStudy to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- PersonPiaoyang Sun
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
- TrialCamrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
- TrialCARES-310
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- TrialCameL
- TreatmentCamrelizumab + rivoceranib
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Hepatocellular carcinoma.
- PersonShukui Qin